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Background: Clinical trials measuring the effect of an intervention on clinical outcomes are more inﬂuential than
those investigating surrogate measures but are costly. We developed methods to reduce costs substantially by
using existing data in primary care systems, to ask whether Helicobacter pylori eradication would reduce the
incidence of hospitalisation for ulcer bleeding in aspirin users.
Methods: The Helicobacter Eradication Aspirin Trial (HEAT) is a National Institute of Health Research-funded,
double-blind placebo controlled randomised trial of the effects ofH. pylori eradication on subsequent ulcer bleed-
ing in infected individuals taking aspirin daily, conducted in practices across the whole of England, Wales and
Northern Ireland. A bespoke web-based trial management system developed for the trial (and housed within
the secure NHSData Network) communicates directlywith the HEAT Toolkit software downloaded at participat-
ing practices, which issues queries searching entry criteria (≥60 years, on chronic aspirin ≤325 mg daily, not on
anti-ulcer therapy or non-steroidal anti-inﬂammatory drugs) for GP review of eligibility. Trial participation is
invited using a highly secure automated online mail management system. Interested patients are seen once for
consent and breath testing. Those with a positive test are randomised to eradication treatment (lansoprazole,
clarithromycin, metronidazole) or placebo, with drug sent by post. Events are tracked by upload of accumulating
information in the GP database, patient contact, review of National Hospital Episode Statistics and Ofﬁce of
National Statistics data.
Results: HEAT is the largest Clinical Research Network-supported drug trial, with 115,660 invitation letters sent
from 850 practices, 22,922 volunteers, and 3038 H. pylori positive patients randomised to active or placebo
treatment after 2.5 years of recruitment. 178practices haveperformed theirﬁrst follow-updata search to identify
21 potential endpoints to date.
Discussion:HEAT is important medically, because aspirin is so widely used, andmethodologically, as a successful
trial would show that large-scale studies of important clinical outcomes can be conducted at a fraction of the cost
of those conducted by industry, which in turn will help to ensure that trials of primarily medical rather than
commercial interest can be conducted successfully in the UK.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Background and Rationale
Clinical trials measuring the effect of an intervention on clinical
outcomes are more inﬂuential than those investigating intermediate
surrogate measures. However, if the outcome occurs infrequently such
studies need to be large, making them costly to conduct. Consequently,Nottingham Digestive Diseases
. This is an open access article underoutcomes studies tend only to be done where there is a substantial
funding source and commercial motivation, resulting in systematic
bias in the information available to prescribers.
The development of cyclooxygenase (COX)-2 inhibitors generated
robust outcomes data about these drugs compared to non-steroidal
anti-inﬂammatory drugs (NSAIDs). Funds have not been available to
conduct similar investigations into low dose aspirin, though prescribing
volumes are higher (http://www.hscic.gov.uk/NHS information centre,
n.d.) and the inﬂuence on peptic ulcer bleeding is now probably greater
(Taha et al., 2007) than for NSAIDs. Moreover understanding how to
prevent ulcer bleeding in patients on aspirin is likely to grow inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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preventing various cancers (Din et al., 2010a), as well as its beneﬁts in
coronary heart disease and cerebrovascular disease. Whilst analgesic
doses of aspirin cause gastroduodenal damage this is much reduced
with the lower doses prescribed for prevention of vascular disease.
The primary aim of the HEAT trial is to investigate the hypothesis
that H. pylori eradication will reduce the incidence of ulcer bleeding in
patients taking aspirin. We therefore investigated how we could
conduct a large scale intervention trial into the prevention of ulcer
bleeding in patients on aspirin within the resources available from
funding bodies for academic studies.
1.2. Objectives and Trial Design
In some epidemiological studies, H. pylori increases the odds of ulcer
bleeding in aspirin users, even in studies which show an opposite effect
for non-aspirin NSAIDs (Stack et al., 2002; Lanas et al., 2002). In
endoscopic studies of patients on low dose aspirin there is a ﬁvefold
increase in ulcer development inH. pylori positive compared to negative
patients (Yeomans et al., 2005). Some studies of secondary prevention
in patients at high risk of ulcer bleeding suggest that H. pylori eradica-
tion may substantially reduce the risk of further events (Chan et al.,
2001; Lai et al., 2002).
HEAT brings together a number of approaches, methods and devices
to streamline a large-scale interventional trial:
• Recruitment in primary care using the MIQUEST (http://
systems.hscic.gov.uk/data/miquest, n.d.) search tool that enables
electronic scrutiny of records in any of the clinical systems used in
UK general practice
• Use of an automated Docmail (http://www.cfhdocmail.com/, n.d.)
postal system that ensures invitations are received within 48 h of
patient identiﬁcation, whilst maintaining record conﬁdentiality
• Useof nurses available through theNational Institute forHealthResearch
(NIHR) Clinical ResearchNetwork (CRN) for the purposes of recruitment
• Using the recruitment visit opportunistically to obtain health check data
to patient and GP beneﬁt, including blood pressure, Body Mass Index,
alcohol consumption and smoking status
• A dedicated central facility for H. pylori analysis
• Despatch of treatment by post
• Replacement of conventional follow-up visits bymultiplemethods for
endpoint ascertainment: participant report, automated scrutiny of GP
records, regular download of hospital episode statistics (HES) and
mortality data, using the secure NHS N3 spine (http://n3.nhs.uk/
technicalinformation/n3networkoverview.cfm, n.d.)
• Validation of endpoints by the adjudication process used in the
TARGET study (Schnitzer et al., 2004)
These methods were selected after validation in a pilot study (HEAT
Trial Pilot Study Report, n.d.), and have several advantages over conven-
tional approaches. They are streamlined, access an unselected popula-
tion, enable predictable and scalable recruitment, and require minimal
manual input of datawhich largely obviates error and theneed formon-
itoring. The process is popularwithGPs because it isminimally intrusive
upon their time, and the recruitment process can also generate patient
health data that returns to the GP record.
HEAT has three objectives:
1. Medical: To test the hypothesis that a one week course of H. pylori
eradication in patients using aspirin ≤325 mg daily will reduce the
incidence of subsequent adjudicated peptic ulcer bleeding that
results in hospitalisation
2. Economic: To test the hypothesis that the intervention has a positive
net monetary beneﬁt
3. Methodological: To establish a methodology for large simple out-
comes studies using electronically extracted primary care follow-updata, to reduce costs to a level that enables outcomes studies of clin-
ically important questions to be done without the need for industry
support
2. Pilot Study
A total of 2525 participants from 9 participating practices in the East
Midlands, South West and North East were invited to undergo H. pylori
testing and eradication. Of those, 1198 (47.4%) replied and 944 (37.4%)
volunteered to participate (897 aged 60+). Positive response rates
ranged from 32.6% to 48.8% with no obvious geographical differences.
Of those who volunteered, 77 were ineligible at initial contact, and a
small number were screen failures, leaving 825 who were enrolled in
the study (87.4% of those initially responding positively). Of these, 184
were positive for H. pylori infection (22.3%) with 12 borderline results
(1.5%). Approximately two months post-eradication all positive partici-
pants had a follow-up appointment for post-treatment breath testing.
Participants and their GPs were notiﬁed of their current H. pylori status;
those who remained positive were referred back to their GP. At follow-
up, 177 (91.3%) of those with an initial positive breath test had a nega-
tive test indicating successful treatment.
In response to a questionnaire, 72% of participants in this non-
randomised study said they would participate in a randomised trial in
which only half the participants were treated during the trial. Results
of the pilot study and logistical experience were used to inform the de-
sign of the main trial.
3. Main Trial
3.1. Methods
3.1.1. Trial Design
HEAT is a double-blind, placebo-controlled, parallel 1:1, randomised
multi-centre trial of the effects of H. pylori eradication treatment vs pla-
cebo on subsequent ulcer bleeding in infected individuals taking aspirin
≤325 mg daily (http://www.controlled-trials.com/ISRCTN10134725/,
n.d.). The protocol was designed by collaborators at the Universities of
Nottingham, Southampton, Durham, Oxford and Birmingham, and the
trial's sponsor is theUniversity of Nottingham. This is currently believed
to be the largest interventional drug trial taking place in the UK, aiming
to contact 170,000 potential participants, consent and breath-test
33,000, and randomise 6600 who are H. pylori positive.
3.1.2. Governance & Ethics
HEAT has been approved by the East Midlands-Leicester Research
Ethics Committee (Ref 11/EM/0434), and theMedicines and Healthcare
products Regulatory Agency (MHRA) (CTA Ref 03057/0052/001-0001)
and is conducted according toGood Clinical Practice and theDeclaration
of Helsinki. The trial was approved by the ethics committee and MHRA
in December 2011, and there has since been one protocol amendment
(to version 2.0, 3-Mar-14), approved for use in April 2014.
3.1.3. Setting
Recruitment takes place solely in primary care, in 145 (former) Prima-
ry Care Trusts (PCTs) spread across England,Wales and Northern Ireland.
This is further to a recent expansion of the trial, from 67 PCTs initially
identiﬁed in 2011. The trial has been adopted by 24 former Comprehen-
sive Local Research Networks (CLRNs) across England, led by Trent CLRN.
Principal Investigators (PIs) are based at 5 regional centres (Nottingham,
Durham, Southampton, Oxford/Birmingham, Belfast). Each practice has a
nominated Study Site Coordinator (SSC) acting under the guidance of the
regional PI, who identiﬁes potentially suitable patients.
3.1.4. Inclusion Criteria
Subjects are males or females ≥60 years of age, taking daily aspirin
≤325mgdaily (4 ormore 28-dayprescriptions in the last year). Subjects
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months), oral NSAIDs or any medication with a clinically signiﬁcant in-
teraction with the H. pylori eradication treatment. Subjects are not ex-
cluded if they have a previous record of H. pylori eradication therapy,
as the success of this is not checked as standard practice in routine care.
3.1.5. Patient Contact
Patients meeting entry criteria are identiﬁed and eligibility is
checked by the SSC. Trial participation is invited using Docmail
(http://www.cfhdocmail.com/, n.d.), a highly secure online mail
management system approved by the ethics committee. Each letter of
invitation has a unique screening number and is accompanied by a
Participant Information Sheet and a reply slip to the regional centre.
3.1.6. Patient Visit and Breath Test
All patients expressing an interest are contacted by telephone to
allow them to ask questions, and invited to attend a screening visit at
their GP practice. Recruitment is performed either by nurses employed
by the regional centre or by suitably trained practice nurses. Trial eligi-
bility is checked andwritten informed consent is obtained. Basic demo-
graphic and health data are recorded before 13C-urea breath testing for
H. pylori (INFAI, (http://www.infai.com/, n.d.)).
A random preselected 10% of participants receive ‘Health-Related
Quality of Life’ questionnaires (for economic analysis) and are re-
breath-tested at the end of the trial to determine the eradication rate
(this sample size gives a +/− 4.5% 95% conﬁdence interval in the rate
estimation), as are all participants experiencing a trial endpoint. All par-
ticipants and their GPs are notiﬁed of their breath test results and those
that are H. pylori positive also receive active or placebo eradication
treatment. Patients with a borderline breath test result are not
randomised, but their GP is informed of the result in case they feel fur-
ther action is required.
3.1.7. Participant Flow Chart3.1.8. Software, Patient Selection & Conﬁdentiality
All trial data are stored on a secure dedicated web server within the
N3 NHS Private Data Network; access is restricted by user identiﬁers
and secure passwords. All participant data is treated conﬁdentially.
A bespoke HEAT web-based database and trial management
system was developed for the trial by TCR Nottingham (http://
tcrnottingham.com/, n.d.). This centralised database communicates
directly with the HEAT Toolkit, a software that is downloaded at partic-
ipating practices.Within the Toolkit, practices issueMIQUEST queries to
their clinical computer system as per the inclusion/exclusion criteria,
and import the responses back for GP manual review of eligibility. An
electronic screening log is generated based on the GP-approved list of
patients.
Prior to consent, only basic information is stored in the trial data-
base: screening number, patient initials, year of birth, and encrypted
NHS Number. Once a participant has consented to the trial, existing
basic information is de-anonymised and relevant healthcare informa-
tion is uploaded into the trial database directly from practice records.
3.1.9. Randomisation and Blinding
A randomisation schedule has been developed by the Nottingham
Clinical Trials Unit (CTU) with separate randomisation sequences for
each regional centre (Nottingham, Durham, Southampton, Oxford/Bir-
mingham, Belfast), using permuted blocks of randomly varying size. In
order to randomise a participant, a web-based randomisation system
is used, which has undergone thorough validity testing by the CTU.
Participants and staff at all sites will be blinded to treatment alloca-
tion. Blinding is maintained as active and placebo treatment kits look
identical. Emergency unblinding will be via a Clinical Trials Pharmacist
at Nottingham University Hospitals NHS Trust.
3.1.10. Trial Treatment
Active treatment is seven days of lansoprazole 30mg, clarithromycin
500mg andmetronidazole 400 mg given twice daily. This regimen was
chosen to match the regimen used in the pilot study, so we are able to
infer comparable eradication rates (this will also be checked by re-
breath testing a 10% sample of patients at the end of the study, and
any patient who experience an endpoint). This regimen is also reputed
to achieve high eradication rates over a shorter treatment duration than
other regimens (Huang and Hunt, 1999). The control group receives
placebos to the same regimen. All medication was manufactured and
packaged by Modepharma (http://www.modepharma.com/, n.d.).
Treatment is dispatched to the participants by post, including a form
on which the participant can log dose timings and record any adverse
effects.
3.1.11. Participant Compliance and Adverse Events
Participants receive a telephone call approximately 7 days following
despatch of medication to check compliance and adverse effects.
Because of the high eradication rates achieved in the pilot study, only
a 10% sample will be retested to conﬁrm successful treatment and indi-
rectly act as a measure of adherence. This is also measured via patient
self-reporting, as all patients are asked to complete a Treatment Record
Form, stating the date and time they take each medication dose.
Serious adverse event data is collected by the GP practices for only
4 weeks from the start of treatment. This is because the trial is classiﬁed
by the MHRA as the lowest risk trial of an investigational medicinal
product (Type A study) (http://www.mhra.gov.uk/Howweregulate/
Medicines/Licensingofmedicines/Clinicaltrials/
Submittinganotiﬁcationforatrial/index.htm, n.d.), using established
medications within their licensed indication. This means that, because
the primary outcome is a safety one, events are not reported after this
time unless the Chief Investigator thinks there are compelling reasons
to implicate treatment in an event detected during subsequent interro-
gation of GP records.
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Participant-reported adverse effects are entered on the trial
database. Participants are asked to inform their Regional Centre of any
hospitalisation but will also be contacted by letter on an annual basis.
They also carry a trial participant ID card which asks hospitals to inform
the Regional Centre of an admission.
GP records are interrogated every 6–12 months by repeated
MIQUEST searches to detect any new Read codes indicating an end-
point, as well as current health and prescribing information.
Participants in this trial consent to their HES and the Ofﬁce of
National Statistics (ONS) Mortality records being accessed, and this
will be downloaded regularly. This information will be matched to
that provided by the MIQUEST search of GP practice records.
3.1.13. Primary and Secondary Outcomes
The primary outcome is hospitalisation due to peptic ulcer bleeding
(only the ﬁrst event per participant will be analysed), adjudicated by a
blinded Adjudication Team as deﬁnite or probable. The three person
GI Adjudication Teamwill adjudicate possible ulcer bleeding endpoints,
as previously done in the TARGET study (Schnitzer et al., 2004).
Secondary endpoints include other causes of GI bleeding, cardiovas-
cular outcomes (APTC endpoint, myocardial infarction, stroke), the
incidence of detected uncomplicated ulcers, ulcer site (duodenal ulcer
vs. gastric ulcer), dyspepsia, and the need for new proton pump inhibitor
(PPI) prescriptions or other prescribed antiulcer/dyspepsia medication.
These data will be collected from electronic searches from GP prac-
tice records, HES and ONS data, and these methods of data acquisition
were validated in the pilot study, and in previous trials (for example,
(Avery et al., 2009)).
3.1.14. Sample Size
A total of 87 events are required to detect a hazard ratio of 0.5
comparing the intervention with the control arm, with a 5% two sided
signiﬁcance level and 90% power. Our power calculations are based on
assumptions derived from event rates in published randomised clinical
trials and observational studies. Based on an average of the rates of ulcer
bleeding in control patients in RCTs and observational studies we as-
sume a rate of 0.16% per annum, in patients not taking aspirin. If aspirin
increases the bleeding rate 2.5 fold we would predict an ulcer bleeding
rate in patients ≥60 years old on aspirin of 0.4% per annum.We assume
approximately 25% of patients are H. pylori positive (as in our pilot
study) and that infection increases the risk threefold. These assump-
tions translate into an ulcer bleeding rate of 0.8% per annum in the
25% of patients who are on aspirin and H. pylori positive. Assuming
event rates of 4 per 1000 per year in the intervention arm and 8 per
1000 per year in the control arm then 7250 person-years are required
per study arm to obtain this number of events and approximately
3300 participants will need to be randomised per study arm (6600
total) assuming an average follow-up of 2.3 years and allowing for 2%
loss to follow-up per year.
3.1.15. Statistical Analysis
A Cox proportional hazards model will be used to analyse time to
ﬁrst episode of hospitalisation because of deﬁnite or probable peptic
ulcer bleeding, to estimate a hazard ratio and 95% conﬁdence interval
comparing treatment arms, adjusted for regional centre. This primary
intention to treat analysis will be supplemented by secondary analyses
that take account of eradication treatment compliance, whether aspirin
is continued and whether a PPI is started.
3.1.16. Health Economics
We will conduct an incremental economic analysis comparing
treated participantswith control participants. The analysis will compare
resource use between the two arms, with key cost drivers for gastric
bleed management being recorded. The economic analysis will be via
Markov decision analysis models, with an assumed life expectancy of14.0 years for men and 16.0 years for women aged 65 or more, with
an indication for aspirin, based on results from the ACTION study
(Clayton et al., 2005).
3.1.17. Post-Trial Care
GP care of participants continues as usual after randomisation. All
participants will be told which arm they were in at the end of the trial,
along with the trial results, to enable them and their GP to make an
informed decision on whether or not eradication therapy for those on
placebo would now be beneﬁcial.
3.1.18. Monitoring and Audits
An important component of this trial is the attempt to develop low-
cost, streamlined, simpliﬁed methodologies to bring outcomes studies
within the affordability of academic investigators. New MHRA guide-
lines from 1 April 2011 are helpful to this aspiration. For Type A trials,
a low-intensity approach to monitoring is advised, taking into account
the trial risk assessment, and speciﬁcs of the trial design. As this is a
low risk trial, with themajority of the study data captured via electronic
methods, required monitoring surrounds just those participants who
experience a trial endpoint.
3.2. Results
After approximately 2.5 years of recruitment, we have now sent out
invitation letters to over 115,000 patients, have heard from almost
23,000 volunteers (~20% volunteering rate), and have consented
17,628 participants to date, 3038 of which have been positive for
H. pylori (17%prevalence). Recruitmentwill continue until 87 adjudicat-
ed endpoints have occurred. We have run follow-upMIQUEST searches
in 178 practices to date, and have identiﬁed 21 potential endpoints in
H. pylori positive participants. Further details will now be collected to
enable adjudication of these events.
3.3. Discussion
HEAT is an innovative trial, bothmedically andmethodologically. If its
hypothesis is supported, it will have identiﬁed a cost effective strategy
that reduces the risk of the adverse events increasingly associated with
the alternative strategy of PPI prophylaxis (Nealis and Howden, 2008).
If there is speciﬁcally a reduction in the incidence of bleeding ulcers, the
results of the trial will strengthen an explanatory paradigm that suggests
that the principal effect of low dose aspirin is an anti-haemostatic rather
than an erosive one, requiring H. pylori infection for the development of
an ulcer that bleeds because of impaired haemostasis. Data that associate
aspirin use more strongly with duodenal than gastric ulceration
(Yeomans et al., 2005; Sostres et al., 2015) may support this paradigm
and an analysis of ulcer site is part of the study plan. With the likely
increase in aspirin use following the recognition of its apparent ability
to prevent and slow cancer growth (Din et al., 2010b), H. pylori eradica-
tion could make a difference to the health of an increasing number of
people, either by supporting a strategy of H. pylori eradication or, in the
event of a negative result, PPI prophylaxis. Application of the trial's results
may differ between countries where its incidence is declining (Calvet
et al., 2013; Axon, 2014) versus those parts of the world where H. pylori
prevalence remains high, as is peptic ulceration and its complications.
Regardless of the trial's results, its methodological advances remain
important for future low-cost outcomes studies.
Our pilot study and the ﬁrst 30months of the current trial show that
assessment and recruitment of large numbers of patients in primary
care is feasible. This is due to the relative ease of screening for patients
using the MIQUEST search tool, with efﬁciency also enhanced by use of
the automated postal system that ensures invitations are received by
several hundred patients per practicewithin 48 h of their identiﬁcation.
Endpoint identiﬁcation via automated Read code searches is perhaps
the most time- and cost-saving element of this trial, removing the
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pants, and increasing the completeness of data recording, which is
often lost with participant- and practice-reported outcomes.
The establishment of the NIHR Clinical Research Network has had a
major inﬂuence in facilitating the trial, which in turn is arguably amodel
of the reach of clinical research that is possible under the auspices of the
CRN. If successful the trial will show that large-scale studies of impor-
tant clinical outcomes across the whole of medicine can be conducted
at a fraction of the cost of those conducted by industry. This will in
turn restore some balance in the generation of data for evidence-
based medicine by increasing the inﬂuence of investigator driven
assessment of clinical issues that are not of direct interest to funding
bodies with substantial funds, such as the pharmaceutical industry.
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